Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
J Prev Alzheimers Dis
; 8(1): 48-51, 2021.
Article
em En
| MEDLINE
| ID: mdl-33336224
ABSTRACT
The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer's Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Peptídeos beta-Amiloides
/
Síndrome de Down
/
Doença de Alzheimer
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
Idioma:
En
Revista:
J Prev Alzheimers Dis
Ano de publicação:
2021
Tipo de documento:
Article